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Only a few cases of hypertriglyceridemia in patients with systemic lupus erythema-
tosus (SLE) have been reported. We report a case of a 13-year-old girl suffering from 
SLE associated with severe hypertriglyceridemia. The persistent hypertriglyceridemia 
was extremely well tolerated. As a result of steroid treatment, serum triglycerides 
fell dramatically from a high of 5601 mg/dL to 75 mg/dL despite the patient switching 
to a free diet. We considered the presence of an autoantibody to lipoprotein lipase 
and commenced immunosuppression. The role of steroids in completely correcting 
deficient lipoprotein lipase activity is discussed.
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1. Introduction
The concept of autoimmune hyperlipidemia was first 
proposed by Beaumont in the 1970s.1,2 Only rarely 
were patients with systemic lupus erythematosus 
(SLE) reported to develop various types of hyperli-
poproteinemia such as type I,3−5 type IIB,4 type III,6 
and type V.7,8 Types I and V hyperlipoproteinemia are 
associated with a decrease in the ability of lipopro-
tein lipase (LPL),9 which is expressed in the paren-
chymal cells of several extrahepatic tissues, to 
hydrolyze the triglycerides (TG) transported in chy-
lomicrons and very-low-density lipoproteins. Several 
reports have shown that LPL de ficiency generally 
results from gene mutations that may affect physi-
ological activator of LPL.10,11 In comparison, acquired 
LPL deficiency is extremely rare.12
In this report, we present a girl with SLE com-
plicated with severe hypertriglyceridemia. The 
persistent hypertriglyceridemia was extremely 
well tolerated. As a result of steroid treatment, 
serum triglycerides fell dramatically from a peak 
of 5601 mg/dL to 75 mg/dL despite the patient 
switching to a free diet. We considered the pres-
ence of an autoantibody to LPL and commenced 
immunosuppression.
2. Case Report
A 13-year-old girl came to the Ren-Ai Branch of 
Taipei City Hospital in July 2006 because of new-
onset low-grade fever (38.0−38.5°C) of 1 week’s 
duration. Before that, she had gone to the beach in 
South Taiwan with her family. Due to the scorching 
sun, she had started to feel uncomfortable.
The patient was l58 cm tall and weighed 44 kg. 
Blood pressure and heart rate were within normal 
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ranges. Physical examination revealed butterfly ery-
thema on her cheeks. The erythema had appeared 
and gradually worsened after the trip to the beach. 
She also had tenderness and mild bulging over bi-
lateral elbows, wrists, metacarpophalangeal joints, 
proximal interphalangeal joints, knees, ankles and 
the soles of her feet. Laboratory examination re-
vealed pancytopenia (white blood cell count, 3610/
µL; red blood cell count, 3.70 × 106/dL; hemoglobin, 
13.1 g/dL; hematocrit, 30.9; platelet count, 114,000/ 
µL). Serologically, antinuclear antibody (2560-fold, 
homogeneous pattern) and anti-dsDNA antibody 
(640-fold) were found. All these symptoms and lab-
oratory results met the criteria for SLE according 
to the American Rheumatism Association.13 Serum 
levels of complements did not decrease (C3, 139 mg/
dL). Urinalysis results were 2 + for occult blood and 
negative for proteinuria; the sediment contained 
6−8 red blood cells with 0−1 white blood cells per 
high-powered field. Thyroid, liver and kidney func-
tion tests were all normal.
However, chylomicronemia was found on routine 
biochemical study, and so the patient’s lipoproteins 
were checked. The results showed that fasting TG 
was a stunning 3240 mg/dL and cholesterol was 
211 mg/dL. Despite the surging numbers, she did not 
feel any discomfort. In addition, bouts of abdominal 
pain, xanthomas and hepatomegaly were not de-
tected. The result of ultrasound examination showed 
normal, but mildly fatty, liver. On the agarose gel 
electrophoresis of serum lipoproteins, the pre-β and 
chylomicron fractions were increased (67.9%, nor-
mal range 8−29%; 3.1%, normal range 0%, respec-
tively). After being stood in the cold for 24 hours, 
the plasma contained a creamy layer over a turbid 
infranatant layer. According to the Fredrickson 
classification,l4 the patient’s lipoprotein pheno -
type was type V hyperlipoproteinemia, suggesting 
defective lipolysis. Her father had mild hypercho-
lesterolemia, but no other abnormalities were 
present in the family. Secondary causes of hypertrigly-
ceridemia were excluded at the first examination 
and in the following 3 months, such as hyperglyce-
mia, pregnancy, hypothyroidism and excess dietary 
fat or alcohol. The presence of an autoantibody to 
LPL was suspected, and so immunosuppression was 
commenced. Oral prednisolone (0.7 mg/kg/day) 
and hydroxychloroquine were started. Fever, ery-
themas, joint symptoms, pancytopenia and micro-
scopic hematuria abated within a week, but serum 
TG remained high (3678 mg/dL). The patient was 
placed on a low-fat diet and followed-up in the 
outpatient clinic with the speculation of LPL defi-
ciency due to an autoimmune process. We had even 
reduced the steroids and added a hypolipidemic 
drug (atorvastatin calcium) for fear of exacerbating 
her hypertriglyceridemia. However, the dose of 
steroids had to be increased due to deteriorating 
hypertriglyceridemia. As a result, serum TG fell dra-
matically from the peak of 5601 mg/dL to 75 mg/dL 
(Figure 1), despite the patient having been switched 
to a free diet. At the same time, serum cholesterol 
level also decreased and returned to normal (Figure 
2). Hypoli pidemic drugs were continued until the 
hypertriglyceridemia was corrected. Prednisolone 
was tapered to the present dose of 0.05 mg/kg/day. 
After a few months, TG continues to be within the 
normal range, and her body weight is 50 kg.
3. Discussion
There have been several previous SLE patients with 
hyperlipidemia.3−8 However, our patient is only 
the third case of type V hyperlipoproteinemia. To 
our knowledge, her hypertriglyceridemia was the 
30 40 30 22.5 17.5 12.5 8.75 5 3.75
6000
Triglyceride
5000
4000
3000
2000
1000
0
9-
Au
g
16
-A
ug
18
-A
ug
23
-A
ug
1-
Se
p
13
-S
ep
27
-S
ep
11
-O
ct
18
-O
ct
1-
N
ov
15
-N
ov
14
-D
ec
28
-D
ec
18
-J
an
1-
Fe
b
15
-F
eb
22
-M
ar
19
-A
pr
17
-M
ay
* Prednisolone (mg/day)
Figure 1  Following medication with steroids, serum triglyceride level decreased to normal. Since the dose of steroids 
was tapered, there was no rebound in triglyceride level during several months. *Between August 13 and 16, steroids 
were reduced to 10 mg/day and a hypolipidemic drug was added for fear of exacerbating hypertriglyceridemia, but 
steroid dose had to be increased due to deteriorating hypertriglyceridemia.
SLE with extreme hypertriglyceridemia 37
highest, without any other symptoms, of all existing 
cases. Previously, hypertriglyceridemia was found 
prior to the diagnosis of SLE, but this case is the only 
exception. It is suspected that the patient already 
suffered from hyperlipidemia but it had not been 
diagnosed. Paucillo et al reported a hypolipidemic 
effect of glucocorticoid therapy in a patient with 
lupus erythematosus.5 In our case, hypolipidemic 
drugs had no obvious effect. The resurging triglyce-
ridemia due to a reduction in the dose of steroids 
and the improvement after reintroduction of immu-
nosuppressive therapy strongly suggests an autoim-
mune origin of this patient’s hypertriglyceridemia.
Borba et al reported that SLE patients had dis-
orders in lipoprotein metabolism, and their LPL ac-
tivities were nearly half of those of a control group.10 
It is also suggested that SLE patients have a lipid 
profile abnormality that is aggravated by disease 
activity. The connection between SLE and LPL defi-
ciency has been long debated. Falko et al detected 
an inhibitor to LPL in the plasma of two SLE patients.4 
Kihara et al reported the presence of immune hy-
perlipoproteinemia caused by autoantibodies against 
LPL in a patient with idiopathic thrombocytopenic 
purpura and Grave’s disease.11 Thus, it is supposed 
that the LPL deficiency in SLE patients is caused by a 
similar autoimmune process. Pruneta et al identified 
the presence of an IgG directed against LPL in an 
autoimmune type I hyperlipidemia patient.12 In vitro, 
this IgG dramatically reduced the LPL-mediated 
lipolysis of TG, thereby demonstrating the putative 
role of this autoantibody in the development of au-
toimmune hyperlipidemia. In addition to autoanti-
body formation, inflammation may induce other 
mechanisms that result in the elevation of TG in SLE 
patients. Tumor necrosis factor-α, interleukin-1 and 
interferon-γ have all been shown to decrease LPL 
enzymatic activity. In lupus patients, there is a strong 
positive correlation between tumor necrosis factor-α 
and plasma TG.
Nakane et al supposed that SLE-induced hyper-
triglyceridemia might be caused by two conditions:8 
immunologic damage to vascular endothelium re-
sulting in an inability to synthesize the LPL protein; 
and presence of an IgG heparin-binding globulin 
inhibiting the release of LPL on administration of 
heparin from the vascular endothelium. However, 
the precise mechanism of the relation between SLE 
and hypertriglyceridemia is not known and remains 
to be elucidated in further studies.
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Figure 2  Serum cholesterol level decreased following steroid therapy and gradually returned to normal.
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